Aurora Spine (ASG) Q2 2024 earnings summary

Executive summary

• Achieved $4.1 million in Q2 2024 revenue, marking the third consecutive quarter above $4 million and a 14.3% increase over Q2 2023, with year-over-year growth of 24%.

• Net loss narrowed to $0.154 million from $0.482 million in Q2 2023, with EPS at $0.00.

• Achieved fourth consecutive quarter of positive EBITDAC, reaching $0.11 million in Q2 2024, a $269,182 improvement year-over-year.

• Gross margin improved to 62.4% from 56.9% year-over-year, reflecting higher-margin product sales and lower distributor commissions.

• Strong demand in the pain market, especially for SiLO TFX and ZIP 51, driven by targeted marketing, expanded sales force, and advanced training initiatives.

Financial highlights

• Revenue for Q2 2024 was $4.08 million, up 14.3% from $3.57 million in Q2 2023.

• Operating expenses rose to $2.74 million, mainly due to higher commissions, salary, and travel costs from sales force expansion.

• Generated $0.348 million in operating cash flow, reflecting effective working capital management.

• Ended Q2 with $0.52 million in cash, up from $0.37 million in Q1, with total assets of $11.99 million.

• Six-month revenue reached $8.05 million, up from $6.48 million, with net loss reduced to $0.42 million from $1.145 million.

Outlook and guidance

• Targeting a $5 million quarter and a $20 million annual run rate, with optimism for continued sales growth in the second half of 2024.

• Management expects net positive income is possible with continued sales increases and cost control.

• No plans or need to raise additional capital, with sufficient cash on hand to support growth.

• Focused on expanding the sales force and targeting underserved markets to drive further growth.

• Continued commitment to innovation and clinical training to support adoption of ZIP and SiLO implants.